Matrix Metalloproteinases and Hypertension-Mediated Organ Damage: Current Insights

References

• Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A. 1962;48(6):1014–1022. doi:10.1073/pnas.48.6.101413902219
   PubMed Web of Science ®Google Scholar
• Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92(8):827–839. doi:10.1161/01.RES.0000070112.80711.3D12730128
   PubMed Web of Science ®Google Scholar
• Cui N, Hu M, Khalil RA. Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci. 2017;147:1–73.28413025
   PubMed Web of Science ®Google Scholar
• Fontana V, Silva PS, Gerlach RF, Tanus-Santos JE. Circulating matrix metalloproteinases and their inhibitors in hypertension. Clin Chim Acta. 2012;413(7–8):656–662. doi:10.1016/j.cca.2011.12.02122245508
   PubMed Web of Science ®Google Scholar
• Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285–292. doi:10.1161/HYPERTENSIONAHA.119.1424031865786
   PubMed Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104.30165516
   PubMed Web of Science ®Google Scholar
• Rubattu S, Pagliaro B, Pierelli G, et al. Pathogenesis of target organ damage in hypertension: role of mitochondrial oxidative stress. Int J Mol Sci. 2015;16(1):823–839. doi:10.3390/ijms16010823
   Web of Science ®Google Scholar
• Morillas P, Quiles J, De Andrade H, et al. Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage. J Hypertens. 2013;31(8):1611–1617. doi:10.1097/HJH.0b013e3283614c1c23615327
   PubMed Web of Science ®Google Scholar
• Nyhan D, Steppan J, Barodka V, Berkowitz DE. Vascular stiffness and increased pulse pressure in the aging cardiovascular system. Cardiol Res Pract. 2011;263585.21845218
   PubMedGoogle Scholar
• Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. Can J Cardiol. 2016;32(5):659–668. doi:10.1016/j.cjca.2016.02.07027118293
   PubMed Web of Science ®Google Scholar
• Parente J, de Castro M. Matrix metalloproteinase in the cardiovascular remodeling of hypertension: current insights and therapeutic potential. Met Med. 2018;5(3):13–30.
   Google Scholar
• Lin J, Davis HB, Dai Q, et al. Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res. 2008;31(6):1225–1231. doi:10.1291/hypres.31.122518716372
   PubMed Web of Science ®Google Scholar
• Wang X, Khalil RA. Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv Pharmacol. 2018;81:241–330.29310800
   PubMedGoogle Scholar
• Marchesi C, Dentali F, Nicolini E, et al. Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis. J Hypertens. 2012;30(1):3–16. doi:10.1097/HJH.0b013e32834d249a22134384
   PubMed Web of Science ®Google Scholar
• Heymans S, Lupu F, Terclavers S, et al. Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice. Am J Pathol. 2005;166(1):15–25. doi:10.1016/S0002-9440(10)62228-615631996
   PubMed Web of Science ®Google Scholar
• Matsusaka H, Ide T, Matsushima S, et al. Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload. Hypertension. 2006;47(4):711–717. doi:10.1161/01.HYP.0000208840.30778.0016505197
   PubMed Web of Science ®Google Scholar
• Rajzer M, Wojciechowska W, Kameczura T, et al. The effect of antihypertensive treatment on arterial stiffness & serum concentration of selected matrix metalloproteinases. Arch Med Sci. 2017;13(4):760–770. doi:10.5114/aoms.2016.5882528721143
   PubMed Web of Science ®Google Scholar
• Lopez-Avila V, Spencer JV. Methods for detection of matrix metalloproteinases as biomarkers in cardiovascular disease. Clin Med Cardiol. 2008;2:75–87. doi:10.4137/CMC.S484
   Google Scholar
• Cheng XC, Fang H, Xu WF. Advances in assays of matrix metalloproteinases (MMPs) and their inhibitors. J Enzyme Inhib Med Chem. 2008;23(2):154–167.18343899
   PubMed Web of Science ®Google Scholar
• Catterall JB, Cawston TE. Assays of matrix metalloproteinases (MMPs) and MMP inhibitors: bioassays and immunoassays applicable to cell culture medium, serum, and synovial fluid. Methods Mol Biol. 2003;225:353–364.12769502
   PubMedGoogle Scholar
• Pintérová M, Kuneš J, Zicha J. Altered neural and vascular mechanisms in hypertension. Physiol Res. 2011;60:381–402. doi:10.33549/physiolres.93218921615201
   PubMed Web of Science ®Google Scholar
• Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38(3 Pt 2):581–587. doi:10.1161/hy09t1.09624911566935
   PubMed Web of Science ®Google Scholar
• Beaudeux JL, Giral P, Bruckert E, Foglietti MJ, Chapman MJ. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives. Clin Chem Lab Med. 2004;42(2):121–131. doi:10.1515/CCLM.2004.02415061349
   PubMed Web of Science ®Google Scholar
• Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology. 2005;56(2):173–189. doi:10.1177/00033197050560020815793607
   PubMed Web of Science ®Google Scholar
• Dai X, Kaul P, Smith SC, Stouffer GA. Predictors, treatment, and outcomes of STEMI occurring in hospitalized patients. Nat Rev Cardiol. 2016;13(3):148–154.26525542
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107(12):1579–1585. doi:10.1161/01.CIR.0000058700.41738.1212668489
   PubMed Web of Science ®Google Scholar
• Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GYH. Matrix metalloproteinase-9 and tissue inhibitor metalloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol. 2000;75(1):43–47. doi:10.1016/S0167-5273(00)00274-611054505
   PubMed Web of Science ®Google Scholar
• Schieffer B, Bünte C, Witte J, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. J Am Coll Cardiol. 2004;44(2):362–368. doi:10.1016/j.jacc.2004.03.06515261932
   PubMed Web of Science ®Google Scholar
• Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GYH. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Hypertens. 2004;17(9):764–769. doi:10.1016/S0895-7061(04)00855-615363817
   PubMed Web of Science ®Google Scholar
• Onal IK, Altun B, Onal ED, Kirkpantur A, Gul OS, Turgan C. Serum levels of MMP-9 and TIMP-1 in primary hypertension and effect of antihypertensive treatment. Eur J Intern Med. 2009;20(4):369–372. doi:10.1016/j.ejim.2008.10.00319524176
   PubMed Web of Science ®Google Scholar
• Donnelly R, Collinson DJ, Manning G. Hypertension, matrix metalloproteinases and target organ damage. J Hypertens. 2003;21(9):1627–1630. doi:10.1097/00004872-200309000-0000912923392
   PubMed Web of Science ®Google Scholar
• Brown IAM, Diederich L, Good ME, et al. Vascular smooth muscle remodeling in conductive and resistance arteries in hypertension. Arterioscler Thromb Vasc Biol. 2018;38(9):1969–1985. doi:10.1161/ATVBAHA.118.31122930354262
   PubMed Web of Science ®Google Scholar
• Van Varik BJ, Rennenberg RJMW, Reutelingsperger CP, Kroon AA, De Leeuw PW, Schurgers LJ. Mechanisms of arterial remodeling: lessons from genetic diseases. Front Genet. 2012;3:290. doi:10.3389/fgene.2012.0029023248645
   PubMedGoogle Scholar
• Renna NF, De Las Heras N, Miatello RM. Pathophysiology of vascular remodeling in hypertension. Int J Hypertens. 2013;2013:808353.23970958
   PubMedGoogle Scholar
• Savoia C, Sada L, Zezza L, et al. Vascular inflammation and endothelial dysfunction in experimental hypertension. Int J Hypertens. 2011;2011:281240. doi:10.4061/2011/28124021915370
   PubMedGoogle Scholar
• Wagenseil JE, Mecham RP. Elastin in large artery stiffness and hypertension. J Cardiovasc Transl Res. 2012;5(3):264–273. doi:10.1007/s12265-012-9349-822290157
   PubMed Web of Science ®Google Scholar
• Roman MJ, Saba PS, Pini R, et al. Parallel cardiac and vascular adaptation in hypertension. Circulation. 1992;86(6):1909–1918. doi:10.1161/01.CIR.86.6.19091451262
   PubMed Web of Science ®Google Scholar
• Munroe PB, Olgunturk RO, Fryns JP, et al. Mutations in the gene encoding the human matrix Gla protein cause keutel syndrome. Nat Genet. 1999;21(1):142–144. doi:10.1038/51029916809
   PubMed Web of Science ®Google Scholar
• Rizzoni D, Porteri E, Boari GEM, et al. Prognostic significance of small-artery structure in hypertension. Circulation. 2003;108(18):2230–2235. doi:10.1161/01.CIR.0000095031.51492.C514557363
   PubMed Web of Science ®Google Scholar
• Mulvany MJ, Baumbach GL, Aalkjaer C, et al. Vascular remodeling. Hypertension. 1996;28(3):505–506.8794840
   PubMed Web of Science ®Google Scholar
• You T, Nicklas BJ. Inflammation and the metabolic syndrome. Med Sci Sports Exerc. 2004;36(Supplement):S1.
   Google Scholar
• Li Y, Wang W, Li L, Khalil RA. MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm. Life Sci. 2020;253:117659. doi:10.1016/j.lfs.2020.11765932283055
   PubMed Web of Science ®Google Scholar
• Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertension. Hypertens Res. 2007;30(10):959–963. doi:10.1291/hypres.30.95918049028
   PubMed Web of Science ®Google Scholar
• Wallace SY, McEniery CM, Dakham Z, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol. 2005;25(2):372–378. doi:10.1161/01.ATV.0000151373.33830.4115556929
   PubMed Web of Science ®Google Scholar
• McNulty M, Mahmud A, Spiers P, Feely J. Collagen type-I degradation is related to arterial stiffness in hypertensive and normotensive subjects. J Hum Hypertens. 2006;20(11):867–873. doi:10.1038/sj.jhh.100201516598292
   PubMed Web of Science ®Google Scholar
• Zhou S, Feely J, Spiers JP, Mahmud A. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens. 2007;21(11):861–867. doi:10.1038/sj.jhh.100224417581602
   PubMed Web of Science ®Google Scholar
• Stakos DA, Tziakas DN, Chalikias GK, Mitrousi K, Tsigalou C, Boudoulas H. Associations between collagen synthesis and degradation and aortic function in arterial hypertension. Am J Hypertens. 2010;23(5):488–494. doi:10.1038/ajh.2010.220134406
   PubMed Web of Science ®Google Scholar
• Medley TL, Kingwell BA, Gatzka CD, Pillay P, Cole TJ. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res. 2003;92(11):1254–1261. doi:10.1161/01.RES.0000076891.24317.CA12750310
   PubMed Web of Science ®Google Scholar
• Kingwell BA, Medley TL, Waddell TK, Cole TJ, Dart AM, Jennings GL. Large artery stiffness: structural and genetic aspects. Clin Exp Pharmacol Physiol. 2001;28(12):1040–1043. doi:10.1046/j.1440-1681.2001.03580.x11903311
   PubMed Web of Science ®Google Scholar
• Riaz S, Zeidan A, Mraiche F. Myocardial proteases and cardiac remodeling. J Cell Physiol. 2017;232(12):3244–3250. doi:10.1002/jcp.2588428255990
   PubMed Web of Science ®Google Scholar
• Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011;3(12):a005058. doi:10.1101/cshperspect.a00505821917992
   PubMed Web of Science ®Google Scholar
• Panek AN, Bader M. Matrix reloaded: the matrix metalloproteinase paradox. Hypertension. 2006;47(4):640–641. doi:10.1161/01.HYP.0000208603.97395.4416505199
   PubMed Web of Science ®Google Scholar
• Hayashidani S, Tsutsui H, Ikeuchi M, et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol. 2003;285(3):H1229–H1235. doi:10.1152/ajpheart.00207.200312775562
   PubMed Web of Science ®Google Scholar
• Laviades C, Varo N, Fernández J, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98(6):535–540. doi:10.1161/01.CIR.98.6.5359714110
   PubMed Web of Science ®Google Scholar
• Zervoudaki A, Economou E, Stefanadis C, et al. Plasma levels of active extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens. 2003;17(2):119–124. doi:10.1038/sj.jhh.100151812574790
   PubMed Web of Science ®Google Scholar
• Zervoudaki A, Economou E, Pitsavos C, et al. The effect of Ca2+ channel antagonists on plasma concentrations of matrix metalloproteinase-2 and −9 in essential hypertension. Am J Hypertens. 2004;17(3):273–276. doi:10.1016/j.amjhyper.2003.11.00715001203
   PubMed Web of Science ®Google Scholar
• López B, González A, Querejeta R, Larman M, Díez J. Alterations in the pattern of collagen deposition may contribute to the deterioration of systolic function in hypertensive patients with heart failure. J Am Coll Cardiol. 2006;48(1):89–96. doi:10.1016/j.jacc.2006.01.07716814653
   PubMed Web of Science ®Google Scholar
• Saglam M, Karakaya O, Esen AM, et al. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects. Tohoku J Exp Med. 2006;208(2):117–122. doi:10.1620/tjem.208.11716434834
   PubMed Web of Science ®Google Scholar
• Zile MR, DeSantis SM, Baicu CF, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Hear Fail. 2011;4(3):246–256. doi:10.1161/CIRCHEARTFAILURE.110.958199
   PubMed Web of Science ®Google Scholar
• Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension. 2004;44(5):595–601. doi:10.1161/01.HYP.0000145180.38707.8415452024
   PubMed Web of Science ®Google Scholar
• Cheng Z, Limbu MH, Wang Z, et al. MMP-2 and 9 in chronic kidney disease. Int J Mol Sci. 2017;18(4):1–11. doi:10.3390/ijms18040776
   Web of Science ®Google Scholar
• Toba H, Lindsey ML. Extracellular matrix roles in cardiorenal fibrosis: potential therapeutic targets for CVD and CKD in the elderly. Pharmacol Ther. 2019;193:99–120. doi:10.1016/j.pharmthera.2018.08.01430149103
   PubMed Web of Science ®Google Scholar
• Rodríguez-Sánchez E, Navarro-García JA, Aceves-Ripoll J, et al. Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. Nefrología. 2019;39(2):184–191. doi:10.1016/j.nefro.2018.08.00930509751
   PubMed Web of Science ®Google Scholar
• Pulido-Olmo H, García-Prieto CF, Álvarez-Llamas G, et al. Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria. Clin Sci. 2016;130(7):525–538. doi:10.1042/CS20150517
   PubMed Web of Science ®Google Scholar
• Friese RS, Rao F, Khandrika S, et al. Matrix metalloproteinases: discrete elevations in essential hypertension and hypertensive end-stage renal disease. Clin Exp Hypertens. 2009;31(7):521–533. doi:10.3109/1064196080266873019886850
   PubMed Web of Science ®Google Scholar
• Xu TY, Zhang Y, Li Y, Zhu DL, Gao PJ. The association of serum inflammatory biomarkers with chronic kidney disease in hypertensive patients. Ren Fail. 2014;36(5):666–672. doi:10.3109/0886022X.2014.89000224575880
   PubMed Web of Science ®Google Scholar
• Sormani MP, Calabrese M, Signori A, Giorgio A, Gallo P, De Stefano N. Modeling the distribution of new MRI cortical lesions in multiple sclerosis longitudinal studies. PLoS One. 2011;6(10):e26712. doi:10.1371/journal.pone.002671222028937
   PubMed Web of Science ®Google Scholar
• Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol. 2012;302(11):F1351–F1361. doi:10.1152/ajprenal.00037.201222492945
   PubMed Web of Science ®Google Scholar